Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Tretten® (coagulation factor XIII A-subunit [recombinant]) logo
Important Safety Information
Prescribing Information
  • About Tretten®
  • Efficacy & Safety
Tretten® (coagulation factor XIII A-subunit [recombinant]) logo

For routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.

Prescribing Information
Important Safety Information

Purely because they are one in a million1

Tretten® is the only recombinant therapy approved for congenital FXIII A-subunit deficiency, a very rare autosomal recessive bleeding disorder that occurs ≈1 in every 3 to 5 million people.2-5

Explore Tretten®

Manny has
congenital
FXIII
deficiency

Molecule icon

Efficacy and safety of Tretten®

Learn more
Folder resources icon

Helping your patients with congenital FXIII A-subunit deficiency

About Tretten®
Speech icon

Learn more about Tretten® dosing and storage

See dosing
Tretten® Lab Program Form
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Tretten® Lab Program Form
Download this form to activate a Labcorp account and participate in the Novo Nordisk Lab Program. Email the completed form to fixsupport@labcorp.com.
Download
Prescribing Information | Important Safety Information
MASAC

The Medical and Scientific Advisory Council (MASAC) recommends the use of Tretten® for patients with congenital FXIII A-subunit deficiency.6

Father and son smiling

NovoCare® is designed for your patients


By creating a NovoCare® account, your patients can access:

  • Product support programs that help with treatment costs
  • Representatives who speak Spanish to better serve more patients

A Novo Nordisk Representative can help you connect patients with these resources. Or you can contact a NovoCare® Specialist by calling 1-844-668-6732.

 

Send your patients to NovoCare.com 

NovoSecure™ is designed for your patients


By creating a NovoSecure™ account, your patients can access:

  • Product support programs that help with treatment costs
  • Representatives who speak Spanish to better serve more patients

A Novo Nordisk Representative can help you connect patients with these resources. Or you can contact a NovoSecure™ Specialist by calling 1-844-668-6732.

 

Send your patients to MyNovoSecure.com 

Selected Important Safety Information for Tretten®

Tretten® is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.

Tretten® may cause allergic reactions. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.

Indications and Usage

Tretten® (Coagulation Factor XIII A-Subunit [Recombinant]) is indicated for routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.

Tretten® is not for use in patients with congenital Factor XIII B-subunit deficiency.

Important Safety Information

Tretten® is contraindicated in patients with hypersensitivity to the active substance or to any of the exicipients.

Tretten® may cause allergic reactions. If signs or symptoms of anaphylaxis or hypersensitivity reactions (including urticaria, rash, tightness of the chest, wheezing, hypotension) occur, discontinue immediately and institute appropriate treatment.

Thromboembolic complications may occur. Monitor patients with conditions that predispose to thrombosis for signs and symptoms of thrombosis after administration of Tretten®.

Inhibitory antibodies may occur with Tretten®. Patients with inhibitory antibodies may manifest as an inadequate response to treatment. If expected plasma FXIII activity levels are not attained, or if breakthrough bleeding occurs while receiving prophylaxis, perform an assay that measures FXIII inhibitory antibody concentrations.

The most common adverse reactions reported in clinical trials (≥1%) were headache, pain in the extremities, pain at injection site, and increase in fibrin D dimer levels. 

Thrombosis may occur if Tretten® is administered concomitantly with Factor VIIa.

There are no adequate and well-controlled studies using Tretten® in pregnant women to determine whether there is a drug-associated risk. Animal reproduction studies have not been conducted with Tretten®.

Please click here for Tretten® Prescribing Information.

References:

  1. Kohler HP, Ichinose A, Seitz R, Ariens RAS, Muszbek L; Factor XIII and Fibrinogen SSC Subcommittee of the ISTH. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost. 2011;9(7):1404-1406.
  2. Tretten [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020. 
  3. U.S. Food and Drug Administration. Licensed biological products with supporting documents. FDA Web Site. Updated August 23, 2021. Accessed February 16, 2022. https://www.fda.gov/vaccines-blood-biologics/licensed-biological-products-supporting-documents
  4. Hsieh L, Nugent D. Factor XIII deficiency. Hemophilia. 2008;14:1190-1200. 
  5. Board PG, Losowky MS, Miloszewski KJA. Factor XIII: inherited and acquired deficienty. Blood Rev. 1993;7:229-242.
  6. National Hemophilia Foundation. MASAC recommendation regarding the use of recombinant clotting factor products with respect to pathogen transmission. http://www.hemophilia.org/sites/default/files/document/files/masac-226.pdf
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support

Tretten® and NovoCare® are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2022 Novo Nordisk All rights reserved. US22TTN00001 April 2022

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials